Equities

JBM (Healthcare) Ltd

JBM (Healthcare) Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.28
  • Today's Change-0.01 / -0.78%
  • Shares traded3.71m
  • 1 Year change+15.32%
  • Beta0.7395
Data delayed at least 15 minutes, as of Nov 11 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

JBM Healthcare Ltd is an investment holding company mainly engages in the marketing and distribution of proprietary Chinese medicines. The Company operates its business through three segments. The Proprietary Chinese Medicines segment mainly distributes over the counter (OTC) proprietary Chinese medicines and concentrated Chinese medicine granule (CCMG) products. The Consumer Healthcare Products segment primarily distributes proprietary medicines in the form of OTC. The Health and Wellness Products segment sales and distributes health and wellness products. The Company operates business in domestic and overseas markets such as Southeast Asia, Europe, and North America.

  • Revenue in HKD (TTM)648.42m
  • Net income in HKD130.46m
  • Incorporated2020
  • Employees279.00
  • Location
    JBM (Healthcare) LtdUnit 2303-07, 23/F, Tower 1, Millennium388 Kwun Tong Road, Kwun Tong, KowloonKOWLOON Hong KongHKG
  • Phone+852 22672178
  • Websitehttps://www.jbmhealthcare.com.hk/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
3D Medicines Inc531.90m-489.36m552.56m193.00--0.5989--1.04-2.08-2.082.233.570.37464.945.792,686,367.00-37.27---50.88--91.97---99.50--2.56--0.2517--11.91--48.78------
Fusen Pharmaceutical Co Ltd462.99m-97.58m702.34m1.14k--1.26--1.52-0.1309-0.13090.62150.75520.32121.685.01403,305.30-6.770.9678-13.961.7453.1851.95-21.082.590.526-2.100.403127.9515.024.13-4.83--0.2124--
Lee's Pharmaceutical Holdings Ltd1.20bn63.06m736.04m993.0011.670.42953.750.61390.10710.10712.042.910.44032.119.701,134,410.001.9813.332.5217.7651.4961.924.5036.200.74256.580.1323.59-14.61-1.53-67.44-47.49-12.19-31.34
Zhaoke Ophthalmology Ltd62.26m-247.07m770.06m297.00--0.3481--12.37-0.4536-0.45360.11424.050.02331.2516.09198,906.50-9.23---10.51--82.03---396.86--5.48-24.020.1114------5.47------
Pak Fah Yeow International Ltd265.21m96.45m779.10m101.008.081.047.512.940.30940.30940.85072.410.28692.8423.532,600,118.0010.443.9911.324.1887.0580.7936.3721.274.225.260.0055100.6876.0612.94250.6623.0218.83-8.06
Zhongzhi Pharmaceutical Holdings Ltd2.22bn121.13m794.51m2.74k6.430.65973.390.35720.1430.1432.631.391.092.687.39841,488.105.997.699.1711.7557.5560.445.496.730.9033213.590.151642.4612.2612.4153.0013.8617.65--
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd912.95m186.77m801.16m678.004.290.46466.390.87760.33340.33341.633.080.35742.102.941,076,590.007.317.6710.2510.4875.4678.7920.4620.681.62--0.05027.22-0.00495.38-23.43-1.67-1.14--
Hbm Holdings Ltd561.09m165.51m911.99m158.005.290.91574.661.630.2250.2250.7611.300.32583.9616.673,170,010.009.59-54.6113.25-66.0495.5797.8129.42-400.283.448.140.3502--120.13127.06116.61---12.62--
Jbm (Healthcare) Ltd648.42m130.46m1.06bn279.008.721.105.771.640.14790.14790.73381.170.46454.255.982,324,068.009.834.3812.045.5252.1446.4721.1612.691.2589.680.115532.9824.6216.09128.5119.992.26--
SinoMab Bioscience Ltd2.20m-217.23m1.33bn214.00--4.42--604.17-0.2085-0.20850.00210.2760.0023----10,253.79-22.83-24.62-29.11-27.7226.80---9,853.75-4,451.74---81.790.6339------14.45--106.81--
Jacobson Pharma Corporation Ltd1.47bn210.24m1.46bn1.72k6.670.60944.150.99480.10950.13910.76441.200.33112.476.37851,885.104.744.305.765.5742.2741.2514.3213.731.735.330.238240.6215.79-0.14011.31-3.0524.064.10
Essex Bio-Technology Ltd1.62bn262.89m1.48bn1.46k5.780.73214.640.91120.44990.44992.733.550.55872.622.731,093,064.009.0711.2012.1014.7389.7886.0116.2419.771.61--0.139716.1629.517.7222.113.567.297.39
Ascletis Pharma Inc10.98m-281.26m1.52bn219.00--0.6617--138.35-0.2709-0.27090.01062.340.00411.343.5850,133.77-10.47-6.43-10.85-6.64-125.1735.67-2,561.69-243.3824.31--0.004--4.63-19.3954.04---20.44--
Data as of Nov 11 2024. Currency figures normalised to JBM (Healthcare) Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.01%Per cent of shares held by top holders
HolderShares% Held
Bessemer Investment Management LLCas of 31 Jul 202452.35k0.01%
Dimensional Fund Advisors LPas of 03 Oct 20241.02k0.00%
American Century Investment Management, Inc.as of 03 Oct 20241.00k0.00%
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.